If approved, the Opdivo-based regimen would be the first immunotherapy-chemotherapy combination approved for this patient population in the EU
With this, the company has secured 511 marketing approvals for its oncology products across 66 countries
The safety profile of the Lunsumio and Polivy combination was consistent with the known profiles of the individual study medicines
Approval of device in Australia for treating locally advanced pancreatic cancer alongside gemcitabine-based chemotherapy
The trial enrolled patients with stage IV pancreatic cancer, where median life expectancy is just 6 to 12 months
The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026
Based on the CRL, the STARGLO data do not provide sufficient evidence to support the proposed second-line DLBCL indication in the US patient population
Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant chemotherapy alone
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
